Idanpaan-Heikkila, J, Alhava, E, Olkinuora, M, Palva, IP. Agranulocytosis during treatment with chlozapine. Eur J Clin Pharmacol
1977; 11: 193–8.
Kane, J, Honigfeld, G, Singer, J, Meltzer, H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry
1988; 45: 789–96.
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet
2013; 382: 951–62.
Lehman, AF, Lieberman, JA, Dixon, LB, McGlashan, TH, Miller, AL, Perkins, DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry
2004; 161 (suppl 2): 1–56.
National Institute for Health and Care Excellence. Psychosis and Schizophrenia in Adults: Prevention and Management. . NICE, 2014.
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. Aust NZ J Psychiatry
2005; 39: 1–30.
Warnez, S, Alessi-Severini, S. Clozapine: a review of clinical practice guidelines and prescribing trends. BMC Psychiatry
2014; 14: 102.
Forrester, T, Siskind, D, Winckel, K, Wheeler, A, Hollingworth, S. Increasing clozapine dispensing trends in Queensland, Australia 2004–2013. Pharmacopsychiatry
2015; 48: 164–9.
Howes, OD, Vergunst, F, Gee, S, McGuire, P, Kapur, S, Taylor, D. Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation. Br J Psychiatry
2012; 201: 481–5.
Clozapine, V. conventional antipsychotic drugs for treatment-resistant schizophrenia: a re-examination. Br J Psychiatry
2003; 183: 161–6.
Booth, A, Clarke, M, Dooley, G, Ghersi, D, Moher, D, Petticrew, M, et al. The nuts and bolts of PROSPERO: an international prospective register of systematic reviews. Syst Rev
2012; 1: 2.
Moher, D, Liberati, A, Tetzlaff, J, Altman, DG. The PRISMA group (2009) preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med
2009; 6: e1000097.
Andreasen, NC, Pressler, M, Nopoulos, P, Miller, D, Ho, BC. Antipsychotic dose equivalents and dose-years: a standardized method for comparing exposure to different drugs. Biol Psychiatry
2010; 67: 255–62.
Leucht, S, Samara, M, Heres, S, Patel, MX, Furukawa, T, Cipriani, A, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull
2015; 41: 1397–402.
Wahlbeck, K, Cheine, M, Essali, A, Adams, C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry
1999; 156: 990–9.
Overall, JE, Gorham, DR. The brief psychiatric rating scale. Psychol Rep
1962; 10: 799–812.
Kay, SR, Fiszbein, A, Opler, LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull
1987; 13: 261–76.
Higgins, JPT, Green, S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. Cochrane Collaboration, 2011.
Andreasen, NC. The Scale for the Assessment of Positive Symptoms (SAPS).
University of Iowa, 1984.
Andreasen, NC. The Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, 1983.
Leucht, S, Rothe, P, Davis, JM, Engel, RR. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol
2013; 23: 956–9.
Azorin, JM, Spiegel, R, Remington, G, Vanelle, JM, Pere, JJ, Giguere, M, et al. A double-blind comparative study of clozapine and risperidone in the management of severe chronic schizophrenia. Am J Psychiatry
2001; 158: 1305–13.
Bitter, I, Dossenbach, MR, Brook, S, Feldman, PD, Metcalfe, S, Gagiano, CA, et al. Olanzapine versus clozapine in treatment-resistant or treatment-intolerant schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry
2004; 28: 173–80.
Bondolfi, G, Dufour, H, Patris, M, May, JP, Billeter, U, Eap, CB, et al. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study. The Risperidone Study Group. Am J Psychiatry
1998; 155: 499–504.
Buchanan, RW, Breier, A, Kirkpatrick, B, Ball, P, Carpenter, WT. Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. Am J Psychiatry
1998; 155: 751–60.
Cao, HJ, You, HF, Fan, FL, Zhang, J. The control study of risperidone and clozapine for the treatment-resistant schizophrenia. J Chinese Med Res
2003; 4: 316–9.
Hong, CJ, Chen, JY, Chiu, HJ, Sim, CB. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol
1997; 12: 123–30.
Kane, JM, Marder, SR, Schooler, NR, Wirshing, WC, Umbricht, D, Baker, RW, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry
2001; 58: 965–72.
Kumra, S, Frazier, JA, Jacobsen, LK, McKenna, K, Gordon, CT, Lenane, MC, et al. Childhood-onset schizophrenia. A double-blind clozapine–haloperidol comparison. Arch Gen Psychiatry
1996; 53: 1090–7.
Kumra, S, Kranzler, H, Gerbino-Rosen, G, Kester, HM, Thomas, C, Kafantaris, V, et al. Clozapine and ‘high-dose’ olanzapine in refractory early-onset schizophrenia: a 12-week randomized and double-blind comparison. Biol Psychiatry
2008; 63: 524–9.
McEvoy, JP, Lieberman, JA, Stroup, TS, Davis, SM, Meltzer, HY, Rosenheck, RA, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry
2006; 163: 600–10.
Meltzer, HY, Bobo, WV, Roy, A, Jayathilake, K, Chen, Y, Ertugrul, A, et al. A randomized, double-blind comparison of clozapine and high-dose olanzapine in treatment-resistant patients with schizophrenia. J Clin Psychiatry
2008; 69: 274–85.
Moresco, RM, Cavallaro, R, Messa, C, Bravi, D, Gobbo, C, Galli, L, et al. Cerebral D2 and 5-HT2 receptor occupancy in schizophrenic patients treated with olanzapine or clozapine. J Psychopharmacol
2004; 18: 355–65.
Naber, D, Riedel, M, Klimke, A, Vorbach, EU, Lambert, M, Kuhn, KU, et al. Randomized double blind comparison of olanzapine vs. clozapine on subjective well-being and clinical outcome in patients with schizophrenia. Acta Psychiatr Scand
2005; 111: 106–15.
Rosenheck, R, Cramer, J, Xu, W, Thomas, J, Henderson, W, Frisman, L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. N Engl J Med
1997; 337: 809–15.
Sacchetti, E, Galluzzo, A, Valsecchi, P, Romeo, F, Gorini, B, Warrington, L, et al. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study. Schizophr Res
2009; 110: 80–9.
Shaw, P, Sporn, A, Gogtay, N, Overman, GP, Greenstein, D, Gochman, P, et al. Childhood-onset schizophrenia: a double-blind, randomized clozapine-olanzapine comparison. Arch Gen Psychiatry
2006; 63: 721–30.
Tollefson, GD, Birkett, MA, Kiesler, GM, Wood, AJ. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine. Biol Psychiatry
2001; 49: 52–63.
Volavka, J, Czobor, P, Sheitman, B, Lindenmayer, JP, Citrome, L, McEvoy, JP, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry
2002; 159: 255–62
Wahlbeck, K, Cheine, M, Tuisku, K, Ahokas, A, Joffe, G, Rimon, R. Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study. Prog Neuropsychopharmacol Biol Psychiatry
2000; 24: 911–22.
Wang, RZ, Geng, YY, Pan, DH, Zhang, SJ. A comparative trial of efficacy of risperidone vs clozapine in treatment of refractory schizophrenia. Chinese J Pharmacoepidemiol
2002; 5: 230–1.
Turner, EH, Matthews, AM, Linardatos, E, Tell, RA, Rosenthal, R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med
2008; 358: 252–60.
Lexchin, J, Bero, LA, Djulbegovic, B, Clark, O. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ
2003; 326: 1167–70.
Stark, A, Scott, J. A review of the use of clozapine levels to guide treatment and determine cause of death. Aust NZ J Psychiatry
2012; 46: 816–25.
Potkin, SG, Bera, R, Gulasekaram, B, Costa, J, Hayes, S, Jin, Y, et al. Plasma clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry
1994; 55 (suppl B): 133–6.
Citrome, L, Ketter, TA. When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract
2013; 67: 407–11.
Dixon, LB, Dickerson, F, Bellack, AS, Bennett, M, Dickinson, D, Goldberg, RW, et al. The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull
2010; 36: 48–70.